7AY1.F ACTINIUM PHARMAC. DL-001

Healthcare Biotechnology Frankfurt Exchange
1.43 EUR
Close of Nov 11, 2026
0.6340 1.43
Market cap
EUR 45.0M
P/E
4.3x
P/B
1.56x
ROE
147.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 7AY1.F undervalued?

Graham number
Price1.43
Graham value2.60
Discount45.1%

7AY1.F trades 45.1% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ACTINIUM PHARMAC. DL-001 fundamental analysis

No fundamental analysis for ACTINIUM PHARMAC. DL-001 yet.

ACTINIUM PHARMAC. DL-001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ACTINIUM PHARMAC. DL-001

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disor…

Full company profile